Ann: Webcast Recording - Investor Presentation and Update, page-6

Mentioned in the company presentation, 22 November

Slide 8
New products and new category opportunities via alliances:

• breast reconstruction
• soft tissue reinforcement
• orthobiologics (bone, tendon, ligament repair)
• delivery of therapeutics (anti-microbials, drug elution, cell-based therapies)

Slide 9

• Alliances with global category leaders and academia for Clinical & Health-economics evidence
• Opportunity to enter breast reconstruction, soft tissue reinforcement, orthobiologics, delivery of therapeutics

Slide 12
Syntrel –

• Targeting the US$2.5bn hernia and abdominal wall reconstruction market via the Syntrel family of products, and currently evaluating several design options with key opinion leaders
• Developing modified NovoSorb products for soft tissue reinforcement
• Breast reconstruction development in-house
• Exploring alliances for Orthobiologics (bone, tendon, ligament regeneration)

• Investigating NovoSorb-based products for Type I diabetes and supplying NovoSorb to Beta-Cell Technologies (3rd party) for clinical trials
• Co-Development of Composite Cultured Skin for single-stage skin replacement
• NovoSorb Drug Elution Depot (pellet), involving the integration of drug treatment into the NovoSorb polymer
• Incorporation of anti-microbials into NovoSorb polymer for controlled release for infection management

It’s a bit unclear, but there definitely seems to be an intention to form alliances for development of orthobiologics (bone, tendon, ligament repair) and therapeutics delivery (anti-microbials, drug elution, cell-based therapies).

Non-academia alliances are expected to be with “global category leaders”.